文献速递心脑血管急症重症综合管理与镇静镇痛

神经丝轻链用于心脏骤停后预后判断——迈向验证的第一步

Neurofilament light chain for prognostication after cardiac arrest-first steps towards validation.
PubMed 文献 · Crit Care · 2025-08-06
一句话结论在心脏骤停后昏迷的院外心脏骤停患者中,24小时神经丝轻链阈值1232 pg/mL和48小时阈值1539 pg/mL对不良神经预后具有98%的特异度,支持最早24小时即可进行可靠的神经预后判断。

本研究基于BOX试验中638例入院时昏迷的院外心脏骤停患者,在24小时或48小时检测血浆神经丝轻链(NfL),以1年时脑功能分类评分(CPC)>2定义为不良神经预后。24小时和48小时NfL预测不良神经预后的AUROC均为0.95。24小时阈值1232 pg/mL和48小时阈值1539 pg/mL的特异度均为98%,假阳性分别为7例(1.4%)和7例(1.3%)。作者认为结果证实了NfL的预后价值,先前确定的阈值表现优异,支持最早在心脏骤停后24小时应用NfL进行可靠的神经预后判断。

要点

  • 在638例入院时昏迷的院外心脏骤停患者中,24小时NfL预测不良神经预后(CPC>2)的AUROC为0.95,48小时亦为0.95。
  • 24小时NfL阈值1232 pg/mL预测不良神经预后的特异度为98%,假阳性7例(1.4%)。
  • 48小时NfL阈值1539 pg/mL预测不良神经预后的特异度为98%,假阳性7例(1.3%)。
  • 作者认为应用NfL可在心脏骤停后最早24小时实现可靠的神经预后判断。
  • NfL是血液神经元损伤标志物,相较目前唯一指南推荐的血标志物神经元特异性烯醇化酶可能具有更早适用的优势。

适用人群与场景

  • BOX试验纳入的院外心脏骤停患者,入院时昏迷。
  • 本分析纳入其中至少有一个24–48小时血浆生物库样本的患者。

诊断标准与关键阈值

  • 不良神经预后定义为1年时脑功能分类评分(CPC)>2。
  • 24小时NfL阈值1232 pg/mL用于预测不良神经预后。
  • 48小时NfL阈值1539 pg/mL用于预测不良神经预后。

研究设计与关键结果

  • 本研究为基于BOX试验的验证性分析,共638例患者在24小时或48小时有NfL检测值。
  • NfL通过ELISA定量,1年时评估脑功能分类评分。
  • 24小时NfL预测不良神经预后的AUROC为0.95,48小时为0.95。
  • 24小时阈值1232 pg/mL预测不良神经预后的特异度为98%,假阳性7例(1.4%)。
  • 48小时阈值1539 pg/mL预测不良神经预后的特异度为98%,假阳性7例(1.3%)。

证据类型、等级与局限

  • 证据类型:基于随机对照试验BOX的验证性分析。
  • 试验注册:ClinicalTrials.gov NCT03141099,注册日期2017年4月30日。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,应用NfL将允许在心脏骤停后最早24小时进行可靠的神经预后判断。
  • 作者认为,先前确定的24小时阈值1232 pg/mL和48小时阈值1539 pg/mL表现优异,具有很高的特异度。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: After cardiac arrest, many patients remain comatose, and a substantial proportion do not survive. Neuroprognostication is essential for identifying patients with potential for recovery, and those with severe, irreversible hypoxic-ischemic brain injury. Neurofilament light chain (NfL) is a blood-based marker of neuronal injury that is under evaluation for neuroprognostication. NfL have potential advantages over the currently only guideline recommended blood biomarker for neuroprognostication, neuron-specific enolase, including earlier applicability. However, there is no consensus on optimal NfL cut-off levels. A previous large investigation in OHCA patients, identified NfL thresholds with high specificity for poor outcome, and the purpose of the present investigation is to validate these cutoffs.

METHODS: The Blood Pressure and Oxygenation Targets in Post Resuscitation Care (BOX) trial included OHCA patients who were comatose at admission. Patients with at least one plasma biobank sample available at 24-48 h were included in this investigation. NfL was quantified by ELISA. Cerebral performance category score was estimated at 1 year. Diagnostic precision of NfL for prediction of poor neurologic outcome (CPC > 2) was determined by area under the receiver operator curve (AUROC), and the performance of previously identified cut-offs for a specificity of 100% were investigated.

RESULTS: A total of 638 patients had a NfL measurement at either 24 or 48 h. The AUROC for prediction of poor neurologic outcome was 0.95 and 0.95 at 24 and 48 h, respectively. At 24 h, a cut-off of 1232 pg/mL had a specificity of 98%, for prediction of poor neurologic outcome, and false-positive results for 7 patients (1.4%). At 48 h, a cut-off of 1539 pg/ml similarly had a specificity of 98%, and false-positive results for 7 patients (1.3%).

CONCLUSIONS: The results of this investigation confirm the prognostic value of NfL for identification of risk of poor neurologic outcome after cardiac arrest. Previously identified cut-offs of 1232 pg/mL at 24 h, and 1539 pg/mL at 48 h, performed excellent with a very high specificity. This indicates that application of NfL will allow for reliable neuroprognostication as early as 24 h after cardiac arrest.

TRIAL REGISTRATION: ClinicalTrials.gov NCT03141099, registered April 30 2017.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Meyer MAS, Beske RP, Mølstrøm S, et al. Neurofilament light chain for prognostication after cardiac arrest-first steps towards validation. Crit Care. 2025. PMID: 40770665. doi:10.1186/s13054-025-05579-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。